Serum insulin-like growth factor binding protein-3 as a potential biomarker for diagnosis and prognosis of oesophageal squamous cell carcinoma

Yun Luoa,b, Chao-Qun Hongc, Bin-Liang Huanga,b,d, Tian-Yan Dinga,b, Ling-Yu Chua,b, Biao Zhanga,b, Qi-Qi Qua,b, Xin-Hao Lia,b, Can-Tong Liua,b,d, Yu-Hui Penga,b,d, Hai-Peng Guoe and Yi-Wei Xua,b,d

aDepartment of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou, China; bPrecision Medicine Research Center, Shantou University Medical College, Shantou, China; cDepartment of Oncological Laboratory Research, the Cancer Hospital of Shantou University Medical College, Shantou, China; dGuangdong Esophageal Cancer Institute, Guangzhou, China; eDepartment of Head and Neck Surgery, the Cancer Hospital of Shantou University Medical College, Shantou, China

ABSTRACT

Background: Insulin-like growth factor binding protein-3 (IGFBP3) has been reported to be related to the risk of some cancers. Here we focussed on serum IGFBP3 as a possible biomarker of diagnosis and prognosis for oesophageal squamous carcinoma (ESCC).

Methods: Enzyme-linked immunosorbent assay (ELISA) was used to measure the serum IGFBP3 level in the training cohort including 136 ESCC patients and 119 normal controls and the validation cohort with 55 ESCC patients and 42 normal controls. The receiver operating characteristics curve (ROC) was used to assess the diagnosis value. Cox proportional hazards model was applied to select factors for survival nomogram construction.

Results: Serum IGFBP3 levels were significantly lower in early-stage ESCC or ESCC patients than those in normal controls (p < .05). The specificity and sensitivity of serum IGFBP3 for the diagnosis of ESCC were 95.80% and 50.00%, respectively, with the area under the ROC curve (AUC) of 0.788 in the training cohort. Similar results were observed in the validation cohort (88.10%, 38.18%, and 0.710). Importantly, serum IGFBP3 could also differentiate early-stage ESCC from controls (95.80%, 52.54%, 0.777 and 88.10%, 36.36%, 0.695 in training and validation cohorts, respectively). Furthermore, Cox multivariate analysis revealed that serum IGFBP3 was an independent prognostic risk factor (HR = 2.599, p = .002). Lower serum IGFBP3 level was correlated with reduced overall survival (p < .05). Nomogram based on serum IGFBP3, TNM stage, and tumour size improved the prognostic prediction of ESCC with a concordance index of 0.715.

Conclusion: We demonstrated that serum IGFBP3 was a potential biomarker of diagnosis and prognosis for ESCC. Meanwhile, the nomogram might help predict the prognosis of ESCC.

KEY MESSAGE

- Serum IGFBP3 showed early diagnostic value in oesophageal squamous cell carcinoma with independent cohort validation. Moreover, serum IGFBP3 was identified as an independent prognostic risk factor, which was used to construct a nomogram with improved prognostic ability in oesophageal squamous cell carcinoma.

Introduction

Oesophageal cancer ranks the seventh in global cancer incidence and the sixth in cancer mortality [1]. Worldwide ESCC is the most common type of oesophageal cancer, which is responsible for 90% of all oesophageal cancers [2]. At the time of diagnosis, patients often developed at advanced stage with lymph node metastasis, which results in a 5-years survival rate of 20%, approximately [3,4]. Extensive lymphatic network of oesophagus and the lack of a protective serosa also lead to the poor prognosis of ESCC. Furthermore, in early stage, ESCC patients are often asymptomatic. This brings about early regional tumour progression, metastasis and delayed diagnosis [5]. ESCC has caused some economic and medical burden. Traditional diagnostic methods include imaging technology and endoscopic examination with biopsy. However, the biopsy is invasive and much painful and
the accuracy of imaging technology such as computer tomography (CT) for differentiating lymph node metastasis and T staging is low only about 50%.[6]. On the other hand, the evaluation of the prognosis of ESCC is mainly based on tumour node metastasis (TNM) stage, but it depends fully on the anatomical range of the carcinoma, which has been proved to be defective for survival analysis of ESCC patients [7]. Thus, convenient and accurate methods for early diagnosis and prognostic assessment of ESCC are urgently needed. Benefiting from technological advances, the development of non-invasive and minimally invasive biomarkers for the early diagnosis and prognosis of ESCC has attracted attention.

The evolutionarily conserved insulin-like growth factor (IGF) is essential for cells growth, development and metabolism [8]. IGFBPs designated as IGFBP1-IGFBP6 can modulate the bioavailability of IGF-I and IGF-II in cellular or circulation environment [9,10]. IGFBPs also regulated the cell cycle, and the function of IGFBPs in transcriptional regulation, DNA damage repair and apoptosis induction suggest that they are closely associated with tumour development, progression, and therapy resistance [11]. For example, IGFBP3 bound with retinoid X receptor (RXR) and increased retinoid-induced transcriptional activity, leading to apoptosis in prostate cancer cells [12]. Furthermore, it was reported that serum IGFBP1 as diagnostic biomarker detected early-stage upper gastrointestinal cancer and serum IGFBP2 may be a biomarker of severe dystrophy and muscle wasting associated with pancreatic ductal adenocarcinoma [13,14].

Researches suggested that active IGFBP3 can regulate cell apoptosis and proliferation in IGF-I dependent or independent pathways [15,16]. IGFBP3 as a tumour suppressor was reported to be down-regulated in some cancers. But some other publications showed its overexpression is associated with poor prognosis for several cancers including pancreatic endocrine neoplasms [11,17]. Meanwhile, epidemiological studies indicated that higher circulating IGF-I : IGFBP3 molar ratio or IGFBP3 level were an increased risk of breast cancer and colorectal cancer [18,19]. Researchers also showed that serum IGFBP3 of colorectal cancer patients was lower than that of normal controls and IGFBP3 as a serum biomarker for colorectal cancer diagnosis has better diagnostic ability than carcinoembryonic antigen (CEA). As well, circular IGFBP3 has the potential to be used as early indicator for colorectal cancer diagnosis [20,21]. Moreover, IGFBP3 as a risk factor for carcinogenesis has been demonstrated in many cancers [22,23]. However, the value of IGFBP3 as a biomarker of diagnosis and prognosis for ESCC remains unclear.

In our study, we investigated whether serum IGFBP3 possessed the potential as a diagnostic and prognostic marker for ESCC. In addition, we attempted to construct a nomogram involving serum IGFBP3 to help improve prediction of survival of ESCC patients.

Materials and methods

Study participants

A retrospective study was developed to access serum IGFBP3 as a potential biomarker for ESCC. Serum samples of patients were collected in the Cancer Hospital of Shantou University Medical College, from March 2013 to July 2014. Serum samples of healthy controls were from Physical Examination Centre in the same hospital, who was identified with health check-up and without suffering any neoplasm. Every patient included in this study conformed to the following standards: (1) ESCC diagnosis was confirmed by histopathological examination; (2) patients did not receive any anti-cancer therapy, or not diagnosed with other carcinomas except ESCC. Tumour stages were evaluated according to the eighth edition American Joint Committee on Cancer (AJCC) Cancer Staging Manual [24]. Early-stage was included stage I and stage II, and advanced stage was included stage III and stage IV. For the diagnostic assessment, ESCC patients and normal controls were randomly divided into a training cohort and a validation cohort in a ratio of approximately 3:1 through the random sampling procedure of SPSS software [25,26]. The peripheral blood samples were coagulated for 30 min at room temperature and centrifuged at 2500 g for 15 min, and serum samples were stored in the biobank of ultra-low temperature refrigerator (−80 °C).

Ethics statement

All participants in this study obtained written informed consent prior to the use of serum samples. This study complied with the Helsinki Declaration and was approved by the institutional ethics review board of Cancer Hospital of Shantou University Medical College, and the ethics approval number is SUMC2011XM-0066.

Enzyme-linked immunosorbent assay (ELISA) for IGFBP3

The concentration of serum IGFBP3 was measured by a commercial ELISA kit (CUSABIO, China) according to
multiplied by the dilution factor. We then poured out the solution from each well in a 100-ul aliquot of biotin-antibody in each well and incubated the microplates for 1 h at 37°C. After washing the plate with wash buffer, 100-ul horse-radish peroxidase-avidin was added to each well and incubated the plate for 1 h at room temperature. Then washing the plate, the microplates were added TMB substrate and incubated for 15–30 min in a dark environment. Stop solution was used to stop the colour formation. The plate microplate reader (Multiskan FC; Thermo Fisher Scientific) was carried out to measure the optical density at 450 nm. Concentrations of IGFBP3 standards for establishing a standard curve were 0, 0.78, 1.56, 3.12, 6.25, 12.5, 25, and 50 ng/mL, respectively. All measurements were repeated. Using the standard curve to obtain serum IGFBP3 concentrations, and actual concentration of serum IGFBP3 must multiplied by the dilution factor.

**Statistical analysis**

SPSS (version 19.0), GraphPad Prism software and R software, version 4.0.4 for windows were applied for statistical analyses. Student’s t-test was implemented to measure the difference of serum IGFBP3 between early-stage ESCC, advanced-stage ESCC or ESCC patients and normal controls. The receiver operating characteristic (ROC) was developed to analyse the predicted probability value. ROC curve was drew to evaluate the optimum predicted probability, specificity and sensitivity of diagnosis and the area under the ROC curve (AUC) with the 95% confidence interval (CI). When the specificity was >90%, through the maximum sensitivity and minimised distance from the cut-off value to the upper left corner of ROC curve to assess cut-off value for diagnosing ESCC [27].

We used X-tile to classify the ESCC patients with higher or lower serum IGFBP3 and changed all continuous variables to categorical variables in prognostic cohort [28]. Pearson’s Chi2 test was used to evaluate the connection between serum IGFBP3 and patient clinical characteristics. Patient survival time and significant difference were calculated by Kaplan–Meier method and log-rank test. We carried out univariate and multivariate Cox regression analysis to search independent risk factors of ESCC prognosis. 1-, 3-, 5-years OS for ESCC patients were predicted by the constructed nomogram. Concordance index (C-index) was applied to analyse the distinction ability of the new model. The accuracy and benefit of the nomogram was evaluated by decision curve analysis (DCA). R packages included ggplot2, ggpubr, survminer and survival were used in analysis. Overall survival (OS) was defined as the time interval from the date of surgical resection to death or last follow-up. In every statistical test, when P values below 0.05 were considered significant, every P values were two-sided.

**Results**

**Serum IGFBP3 levels in ESCC patients and normal controls**

This study recruited 352 participants (Figure 1). The training cohort included 136 ESCC patients (59 early-stage patients) and 119 normal controls. 55 ESCC patients (22 early-stage patients) and 42 normal controls involved in the validation cohort. Clinical characteristics of two cohorts were shown in Table 1.

The serum IGFBP3 levels of ESCC patients and normal controls in two cohorts were tested by ELISA, as shown in Figure 2. Serum IGFBP3 levels (mean ± SD) of patients (22 early-stage patients) and 42 normal controls was 0.788 (95% CI, 0.733–0.844) in training cohort (1096.573 ± 613.766 ng/mL, 1119.625 ± 580.810 ng/ml or 1109.624 ± 593.200 ng/ml vs 1684.814 ± 354.828 ng/mL, p < .05). The results in validation cohort were consistent (1262.475 ± 476.643 ng/mL, 1179.240 ± 526.914 ng/ml or 1212.533 ± 504.550 ng/ml vs 1602.566 ± 490.362 ng/ml, p < .05). However, there is no significant different in comparison of serum levels of IGFBP3 between early-stage and advanced-stage ESCC patients (p > 0.05).

**Diagnostic ability of IGFBP3 to differentiate ESCC and normal control**

For diagnosis of ESCC, ROC curve analysis showed that the AUC of IGFBP3 to differentiate ESCC from normal controls was 0.788 (95% CI, 0.733–0.844) in training cohort (Figure 3(A)). The sensitivity was 50.00% when the specificity was 95.80%. Results were confirmed in validation cohort, with the AUC of 0.710 (95% CI, 0.658–0.812), specificity of 88.10% and sensitivity of 38.18% (Figure 3(B)). In both cohorts the cut-off value of 1026 ng/ml was consistent.

Early diagnostic performances were also accessed by ROC analysis. The AUC of serum IGFBP3 to discriminate early-stage ESCC patients from normal controls was 0.777 (95% CI, 0.697–0.856), the specificity was 95.80% and the sensitivity was 52.54% in train cohort.
Figure 1. Study overview of serum IGFBP3 in oesophageal squamous cell carcinoma.

Table 1. Clinical characteristics of samples in two cohorts.

| Variables                      | Training cohort | Validation cohort |
|--------------------------------|-----------------|-------------------|
|                                | ESCC (n = 136)  | normal (n = 119)  |
|                                | ESCC (n = 55)  | normal (n = 42)  |
| Age                            |                 |                   |
| Mean ± SD                      | 58 ± 8          | 55 ± 11           |
| Range                          | 41–83           | 36–83             |
| Gender                         |                 |                   |
| Female                         | 32              | 48                |
| Male                           | 104             | 67                |
| Unknown                        | 4               | 4                 |
| Smoke                          |                 |                   |
| No                             | 93              | 36                |
| Yes                            | 43              | 65.5              |
| Alcohol drinking               |                 |                   |
| No                             | 95              | 95                |
| Yes                            | 41              | 30.1              |
| location of tumour             |                 |                   |
| Upper oesophagus               | 20              | 14.7              |
| Middle oesophagus              | 99              | 72.8              |
| Lower oesophagus               | 17              | 12.5              |
| Size of tumour                 |                 |                   |
| ≤5 cm                          | 98              | 72.1              |
| >5 cm                          | 38              | 27.9              |
| Histological grade             |                 |                   |
| High (Grade 1)                 | 28              | 20.6              |
| Middle (Grade 2)               | 84              | 61.8              |
| Low (Grade 3)                  | 15              | 11.0              |
| Unknown                        | 9               | 6.6               |
| Depth of tumour invasion       |                 |                   |
| T1 + T2                        | 25              | 18.4              |
| T3 + T4                        | 111             | 81.6              |
| Lymph node metastasis          |                 |                   |
| N0                             | 70              | 51.5              |
| N1 + N2 + N3                   | 66              | 48.5              |
| TNM stage                      |                 |                   |
| Early stage (I + II)           | 59              | 43.4              |
| Advanced stage (III + IVA)     | 77              | 56.6              |

TNM: tumour node metastasis.
Figure 2. Serum IGFBP3 level. Median and interquartile range of serum IGFBP3 level in early-stage ESCC, advanced-stage ESCC, ESCC patients and normal controls in two cohorts (A: training cohort; B: validation cohort). Unpaired t test was applied to evaluate the IGFBP3 difference of early-stage ESCC, advanced-stage ESCC or ESCC patients and normal control in two cohorts.

Figure 3. ROC curve of IGFBP3 in ESCC diagnosis. ROC curves of serum IGFBP3 to distinguish ESCC patients and normal controls in two cohorts (A: training cohort; B: validation cohort), and diagnostic value of early-stage ESCC in two cohorts (C: training cohort; D: validation cohort).
(Figure 3(C)). With the same cut-off value from training cohort, the AUC was 0.695 (95% CI, 0.561–0.828) and diagnostic specificity and sensitivity were 88.10% and 36.36%, respectively, in the validation cohort (Figure 3(D)). The predictive values and the likelihood ratios of serum IGFBP3 for improving the clinical interpretation of the diagnosis of early-stage ESCC and ESCC were also shown in Table 2.

**Prognostic value of serum IGFBP3 in ESCC**

We explored whether serum IGFBP3 could be applied for predicting prognosis. Among the 191 ESCC patients recruited in this study, 26 patients lacked complete follow-up data and were not included for prognostic analysis. Therefore, the prognostic cohort included 165 ESCC patients. Moreover, the maximum and median follow-up survival time for ESCC patients were 77 months and 55 months, respectively.

We assessed the association of serum IGFBP3 with clinical parameters using the Pearson’s Chi2 test. Using X-tile, the cut-off value of IGFBP3 was defined as 1087.02 ng/ml. As displayed in Table 3, the correlated relationship between serum IGFBP3 levels and clinical features was not significant. Univariate Cox analysis indicated that smoking, depth of tumour invasion, TNM stage, tumour size, lymph node metastasis and serum IGFBP3 were prognostic factors of ESCC. Multivariate Cox analysis further suggested that TNM stage (p = .045, HR = 0.370, 95% CI: 0.140–0.980), tumour size (p = .003, HR = 0.415, 95% CI: 0.232–0.743) and serum IGFBP3 (p = .002, HR = 2.599, 95% CI:

| Group | AUC (95% CI) | Specificity | Sensitivity | NPV | PPV | NLR | PLR |
|-------|--------------|-------------|-------------|-----|-----|-----|-----|
| Training cohort | | | | | | | |
| ESCC vs. normal controls | 0.788 (0.733–0.844) | 95.80% | 50.00% | 62.64% | 93.15% | 0.52 | 11.9 |
| Early-stage ESCC vs. normal controls | 0.777 (0.697–0.856) | 95.80% | 52.54% | 80.28% | 86.11% | 0.5 | 12.51 |
| Validation cohort | | | | | | | |
| ESCC vs. normal controls | 0.710 (0.608–0.812) | 88.10% | 38.18% | 52.11% | 80.77% | 0.7 | 3.21 |
| Early-stage ESCC vs. normal controls | 0.695 (0.561–0.828) | 88.10% | 36.36% | 72.55% | 61.54% | 0.72 | 3.06 |

AUC: area under the curve; NPV: negative predictive value; PPV: positive predictive value; NLR: negative likelihood ratio; PLR: positive likelihood ratio; 95% CI: 95% confidence interval.

| Variables | IGFBP3 protein | All cases | Low IGFBP3 level | High IGFBP3 level | p Value |
|-----------|----------------|-----------|------------------|------------------|---------|
| Age | | | | | |
| ≤68 | 140 | 76 | 64 | .368 |
| >68 | 25 | 16 | 9 | |
| Gender | | | | | |
| Female | 43 | 27 | 16 | .280 |
| Male | 122 | 65 | 57 | |
| Smoke | | | | | |
| No | 52 | 28 | 24 | .737 |
| Yes | 113 | 64 | 49 | |
| Alcohol drinking | | | | | |
| No | 108 | 63 | 45 | .359 |
| Yes | 57 | 29 | 28 | |
| Location of tumour | | | | | |
| Upper oesophagus | 24 | 13 | 11 | .712 |
| Middle oesophagus | 114 | 62 | 52 | |
| Lower oesophagus | 27 | 17 | 10 | |
| Size of tumour | | | | | |
| ≤5 cm | 121 | 71 | 50 | .210 |
| >5 cm | 44 | 21 | 23 | |
| Histological grade | | | | | |
| High (Grade 1) | 35 | 19 | 16 | .524 |
| Middle (Grade 2) | 97 | 51 | 46 | |
| Low (Grade 3) | 17 | 12 | 5 | |
| Unknown | 16 | 10 | 6 | |
| Depth of tumour invasion | | | | | |
| T1 + T2 | 40 | 21 | 19 | .634 |
| T3 + T4 | 125 | 71 | 54 | |
| Lymph node metastasis | | | | | |
| NO | 92 | 49 | 43 | .469 |
| N1 + N2 + N3 | 73 | 43 | 30 | |
| TNM stage | | | | | |
| Early stage (I + II) | 76 | 40 | 36 | .455 |
| Advanced stage (III + IVA) | 89 | 52 | 37 | |
1.412–4.784) were independent factors to predict the prognosis of ESCC (Table 4). Furthermore, log-rank test and Kaplan–Meier revealed that the OS of ESCC patients with lower serum IGFBP3 level was shorter than those with higher serum IGFBP3 level, and the number of people alive at each time point in the both groups was also showed ($p = .0057$) (Figure 4(A)). In addition, we further drew an adjusted survival curve (covariates including size of tumour, smoking, TNM stage, lymph node metastasis and depth of tumour invasion) for serum IGFBP3 and confirmed serum IGFBP3 level was related to patient survival time (Figure 4(B)).

**Nomogram for OS of ESCC**

For better evaluating prognosis of ESCC, we constructed a nomogram to forecast 1-, 3- and 5-years OS.

| Variables                                | Univariate analyses | Multivariate analyses |
|------------------------------------------|---------------------|-----------------------|
|                                          | HR (95% CI)         | $p$ Value             | HR (95% CI)         | $p$ Value             |
| Age ($<68$ vs $>68$)                     | 0.788 (0.384–1.617) | .516                  |                      |                      |
| Gender (female vs male)                  | 0.600 (0.292–1.231) | .163                  |                      |                      |
| Smoke (no vs yes)                        | 0.484 (0.243–0.965) | .039                  |                      |                      |
| Alcohol drinking (no vs yes)             | 0.634 (0.366–1.096) | .103                  |                      |                      |
| Location of tumour                       | 0.291 (0.079–1.075) | .064                  |                      |                      |
| Upper oesophagus vs Lower oesophagus     | 0.925 (0.449–1.906) | .832                  |                      |                      |
| Middle oesophagus vs Lower oesophagus    | 0.346 (0.201–0.597) | <.001                 | 0.415 (0.232–0.743) | .003                 |
| Size of tumour                           | 0.493 (0.190–1.279) | .146                  | 0.417 (0.188–0.924) | .031                 |
| Histological grade                       | 0.683 (0.315–1.479) | .333                  |                      |                      |
| G1 vs G3                                 | 0.413 (0.236–0.723) | .002                  |                      |                      |
| Depth of tumour invasion                 | 0.311 (0.166–0.583) | <.001                 | 0.370 (0.140–0.980) | .045                 |
| T1 + T2 vs T3 + T4                       |                      |                       | 0.269 (1.245–4.135) | .007                 |
| Lymph node metastasis                    |                      |                       | 0.599 (1.412–4.784) | .002                 |
| N0 vs N1 + N2 + N3                       |                      |                       | 0.370 (0.140–0.980) | .045                 |
| T1 + T2 vs T3 + T4                       |                      |                       | 0.269 (1.245–4.135) | .007                 |
| TNM stage                                |                      |                       | 0.599 (1.412–4.784) | .002                 |
| early stage vs Advanced stage            |                      |                       | 0.370 (0.140–0.980) | .045                 |
| IGFBP3 (lower vs higher)                 | 2.269 (1.245–4.135) | .007                  | 2.599 (1.412–4.784) | .002                 |

HR: hazard ratio; 95% CI: 95% confidence interval; OS: overall survival.

**Figure 4.** Kaplan–Meier curves for OS. (A) survival curve for serum IGFBP3 with ESCC patients, Log-rank test was used to evaluate the significant difference. (B) adjusted survival curves for serum IGFBP3 with ESCC patients. The number of people alive at each time point in the high and low IGFBP3 groups was showed in “number at risk.”
based on TNM stage, size of tumour and serum IGFBP3 (Figure 5). In the nomogram, “points” were obtained according to different levels of individual predictors, and these points were added together to get “total points”. We painted a straight line down from the “total points” line to intersect the lines of 1-, 3- and 5-years OS, where the intersection was the survival rates of 1-, 3- or 5-years. As shown in Table 5, the C-index of nomogram (0.715, 95%CI: 0.683–0.747) was higher than those of TNM stage (0.641, 95%CI: 0.611–0.671, \( p < .05 \)), size of tumour (0.610, 95%CI: 0.577–0.643, \( p < .05 \)) or serum IGFBP3 (0.604, 95%CI: 0.572–0.636, \( p < .05 \)). The C-index curve contrasted with each single variable based on time distribution of three and five years and validated by bootstrap algorithm were plotted (Figure 6). The calibration curve revealed that the prediction accuracy of nomogram for OS was improved (Figure 7). Net benefit was displayed by DCA as shown in Figure 8, of which represented the nomogram to predict OS was better than those of other risk indicators. Then, we calculated the predicted total points according to nomogram and got the best cut-off value for OS (192.5) through X-tile. We divided ESCC patients into lower risk group or higher risk group according to the best cut-off value.

Kaplan–Meier survival analysis and log-rank test confirmed that the OS of patients in the group of higher risk was shorter than those in the group of lower risk (\( p < .0001 \), Figure 9).

**Discussion**

The geographic distribution of ESCC varies widely. The region with the highest incidence extends from East Asia to Central Asia. With the difference in geographical distribution, ESCC is highly prevalent in Asia, while the pathological type of oesophageal cancer in Europe is mainly oesophageal adenocarcinoma [2]. Pathophysiological differences and changes in the oesophageal cancer microenvironment are barriers to

**Table 5.** C-index of IGFBP3, size of tumour, TNM stage and nomogram of prediction for OS.

| Factors     | C-index (95% CI)       | \( p \) Value |
|-------------|------------------------|---------------|
| For OS      |                        |               |
| IGFBP3      | 0.604 (0.572–0.636)    |               |
| Size of tumour | 0.610 (0.577–0.643)  |               |
| TNM stage   | 0.641 (0.611–0.671)    |               |
| Nomogram    | 0.715 (0.683–0.747)    | <.001         |
| Nomogram vs IGFBP3 | <.004       |               |
| Nomogram vs size of tumour | .015        |               |
| Nomogram vs TNM stage |        |               |

nomogram: serum IGFBP3 + size of tumour + TNM stage.
developing biomarkers for early detection of oesophageal cancer \[29\]. These facts make it challenge to find promising early diagnostic markers for ESCC. Some blood-based biomarkers were clinically detected such as cytokeratin-19 fragment (CYFRA21-1), squamous cell carcinoma antigen (SCC-Ag) and carcinoembryonic antigen (CEA). However, these biomarkers lack evidence as early diagnostic biomarkers \[30,31\]. The endoscopic-biopsy approach is widely applied in clinic for the detection of oesophageal cancer and preinvasive lesions, but invasive experiences during examination and capacity of endoscopy and pathological professionals limit its extensive utilisation for the screening of asymptomatic populations. This method requires highly skilled endoscopists, which at present are not widely available in rural areas with high ESCC incidence most in need of effective screening. It’s conceivable that a robust blood-based biomarker test that could be used in the early or asymptomatic stage of ESCC as the primary screening method would concentrate the population and further avoid unnecessary invasive procedure. Here, our study found serum IGFBP3 has potential diagnostic efficacy for early-stage ESCC and ESCC patients. We think that the non-invasive biomarker test of IGFBP3 is not meant to replace endoscopy, but to help identify patients who might harbour ESCC at an earlier stage.

Meanwhile, another dilemma is the prognostic assessment of ESCC. An accurate evaluation approach is the hinge to postoperative treatment selection and prognosis judgement of ESCC patients. At present, clinical staging mainly relies on the TNM stage system \[32\]. However, stage results may be affected by pathological assessment and tumour heterogeneity \[33\]. Studies showed that the combined application of some biomarkers and clinicopathological parameters were feasible to improve the accuracy of prognosis prediction in ESCC \[34\]. Through our study, we identified that serum IGFBP3 was an independent prognostic factor, and patients with the lower serum IGFBP3 indicated worse OS. Similar result was reported that the radiotherapy response of ESCC patients with

\[A\]

\[B\]

\[C\]

\[D\]

Figure 6. C-index curve to evaluate the predicted ability of the nomogram, C-index curve under the time distribution of 3 years (A) and five years (C) and internal verification by Bootstrap algorithm of three years (B) and five years (D).
elevated protein level of IGFBP3 was improved and overall survival was prolonged [35]. Besides, OS, event-free survival and progression-free survival (PFS) of primary non-small cell lung cancer (NSCLC) patients with reduced IGFBP3 expression were shorter [36]. However, researches also indicated that serum IGFBP3 was not an independent prognostic indicator in multiple myeloma and breast cancer [37,38]. These results implied that serum IGFBP3 might have different prognostic significance in different carcinomas, and the prognostic potential of serum IGFBP3 in cancer should be further evaluated. In our study, the nomogram based on serum IGFBP3, size of tumour and TNM stage provided more precise prognostic prediction. The C-index of the nomogram was better than those three indicators. The decision curve and calibration curve indicated that the nomogram as a comprehensive evaluation model improved predictive ability for 1-year, 3-years and 5-years OS of ESCC patients.

Previous studies paid more attention to the correlation between IGFBP3 and the risk of oesophageal cancer. It is reported that, after adjusting the influence of BMI, smoking and drinking, serum IGFBP3 level and molar differences in serum IGFBP3-IGF1 were inversely related to the risk of oesophageal cancer in an epidemiological research, and individuals with lower level of IGFBP3 were more possibly to develop oesophageal cancer [39,40]. These studies indicated IGFBP3 as a risk factor for oesophageal cancer. Our study revealed that serum IGFBP3 may be a biomarker for diagnosis and prognosis of ESCC. We found the serum IGFBP3 level was significantly lower in early-stage ESCC patients than those in normal controls. This is consistent with the research of YILMAZ et al, who carried out a small sample size study with 40 oesophageal carcinoma patients and 40 controls and did not analyse the diagnostic/prognostic value of IGFBP3 [41]. Compared to YILMAZ et al.’s research, the advantages of our study should be highlighted, which was designed in lager sample size with independent cohort validation. Several studies to support the lower level of serum IGFBP3 in oesophageal cancer patients, which was negatively correlated with the
positive expression of IGFBP3 in tissues, was higher than that in the normal controls in peripheral blood. And the positive rate of IGFBP3 in EC tissues was significantly lower than that in adjacent normal tissues [42]. These results suggest that methylation status of IGFBP3 may be related to the low expression of serum IGFBP3 in ESCC. In addition, serum IGFBP3 level was also lower in colorectal cancer compared with normal controls. Methylation of the IGFBP3 promoter and protease degradation such as matrix metalloproteinase-7 (MMP-7) for IGFBP3 were considered as the regulatory mechanism which may induce the low IGFBP3 level in colorectal cancer [20,43,44]. These evidences indicated that IGFBP3 may be regulated by multiple regulations.

In the future, further studies are warranted to explore the mechanisms of the low expression of IGFBP3 in ESCC.

Some limitations existed in this study. First, although serum IGFBP3 showed diagnosis value for ESCC in both cohorts, the diagnostic performance of the validation cohort appeared to be inferior to that of the training cohort. This result may be due to the smaller sample size of patients and normal controls in the validation cohort. It seems inevitable that different sample sizes or different sample sources would lead to such bias. In addition to sample size difference between the two groups, the proportions of patients with different clinical features also varied. This might

**Figure 8.** Decision curve analysis of serum IGFBP3, size of tumour, TNM stage and nomogram, A-C shown the decision curve for 1 year, 3 years, and 5 years of OS.
also bring about the distinction in results for diagnostic performance to some degree. Actually, many studies on biomarker diagnosis evaluation showed obviously different results in different cohorts because of different sample sizes and different proportions of patients [45,46]. To overcome this problem, we believe that more different cohorts with large samples were required to be included to assess the diagnostic ability of serum biomarker. Moreover, as IGF-I bioactivity is partially regulated through IGFBPs, with ~80% bound to IGFBP3 [47,48], studies tended to investigate the associations of circulating IGF-I and IGFBP3 levels and analyse their roles simultaneously in cancers. However, our current study lacks examination of the serum level of IGF-I and its relationship with serum IGFBP3. IGF-I has been implicated in the development and progression of a variety of cancers. It was reported that IGF-I derived from adipose tissue improved cell growth and inhibited cell apoptosis of ESCC [49]. Therefore, in future study, it is an important point to combine detection of serum IGF-I and IGFBP3 and explore their biological functions.

**Conclusion**

We found evidence of serum IGFBP3 with potential diagnostic and prognostic value for ESCC. The differential expression level and the early diagnostic value of serum IGFBP3 confirmed in two cohorts, which indicated it might be applied as an early diagnostic biomarker. Moreover, our studies confirmed that serum IGFBP3 was an independent prognostic risk factor of ESCC and the nomogram containing serum IGFBP3 was constructed to facilitate the survival prediction of ESCC.

**Author contributions**

Yun Luo and Chao-Qun Hong: study design; data analysis; statistical analysis and drafting of the manuscript. Bin-Liang Huang, Tian-Yan Ding, Ling-Yu Chu and Biao Zhang: data analysis and interpretation and statistical analysis. Qi-Qi Qu, Xin-Hao Li, and Can-Tong Liu: data acquisition and analysis and study supervision. Yu-Hui Peng, Hai-Peng Guo, Yi-Wei Xu: critical revision of the manuscript; obtained funding and administrative, technical, or material support; equal contribution of this work. All authors have approved the final version and agreed to publish the manuscript.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This work was supported by the Natural Science Foundation of China [grant number 81972801]; Guangdong Basic and Applied Basic Research Foundation [grant number 2019A1515011873]; Guangdong Esophageal Cancer Institute Science and Technology Program [grant number Q201906]; Science and Technology Special Fund of Guangdong Province of China [grant number 210729156901797; 1908291015545145] and the 2020 Li Ka Shing Foundation Cross-Disciplinary Research Grant [grant number 2020LKSFG01B].

**Data availability statement**

The data that support the findings of this study are available on request from the corresponding author, [Yi-Wei Xu]. The data are not publicly available due to restrictions e.g. their containing information that could compromise the privacy of research participants.

**References**

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249.

[2] Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–373.

[3] Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet (London, England). 2013;381(9864):400–412.

[4] Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–2252.
[5] Reichenbach ZW, Murray MG, Saxena R, et al. Clinical and translational advances in esophageal squamous cell carcinoma. Adv Cancer Res. 2019;144:95–135.

[6] Lee G, I H, Kim SJ, et al. Clinical implication of PET/ MR imaging in preoperative esophageal cancer staging: comparison with PET/CT, endoscopic ultrasonography, and CT. J Nucl Med. 2014;55(8):1242–1247.

[7] Chen X, Yu Y, Wu H, et al. A novel model combining tumor length, tumor thickness, TNM stage, nutritional index, and inflammatory index might be superior to the 8th TNM staging criteria in predicting the prognosis of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Front Oncol. 2022;12:896788.

[8] Sonntag WE, Csiszar A, deCabo R, et al. Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: progress and controversies. J Gerontol A Biol Sci Med Sci. 2012;67(6):587–598.

[9] Burren CP, Wilson EM, Hwa V, et al. Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-P3/NovH), an additional member of the IGFBP superfamily. J Clin Endocrinol Metab. 1999;84(3):1096–1103.

[10] Miyamoto S, Nakamura M, Yano K, et al. Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix. Cancer Sci. 2007;98(5):685–691.

[11] Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14(5):329–341.

[12] Liu B, Lee HY, Weinheimer SA, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem. 2000;275(43):33607–33613.

[13] Dong J, Yu J, Li Z, et al. Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting. Journal of Cachexia, Sarcopenia and Muscle. 2021;12(3):704–716.

[14] Xu YW, Chen H, Hong CQ, et al. Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour. EBioMedicine. 2020;51:102566.

[15] Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30(5):417–437.

[16] Valentinis B, Bhala A, DeAngelis T, et al. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol. 1995;9(3):361–367.

[17] Hansel DE, Rahman A, House M, et al. Met protooncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res. 2004;10(18 Pt 1):6152–6158.

[18] Key TJ, Appleby PN, Reeves GK, et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530–542. Jun

[19] Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in Northern Sweden. Gut. 2002;50(5):642–646.

[20] Hou YL, Luo P, Ji GY, et al. Clinical significance of serum IGFBP-3 in colorectal cancer. J Clin Lab Anal. 2019;33(6):e22912.

[21] Probst-Hensch NM, Yuan JM, Stanczyk FZ, et al. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of chinese men in shanghai. Br J Cancer. 2001;85(11):1695–1699.

[22] Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and Meta-regression analysis. Lancet (London, England). 2004;363(9418):1346–1353.

[23] Chen B, Liu S, Xu W, et al. IGF-I and IGFBP-3 and the risk of lung cancer: a Meta-analysis based on nested case-control studies. J Exp Clin Cancer Res. 2009;28(1):89.

[24] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99.

[25] Huang Q, Xu TY, Wu ZY. Construction and validation of nomograms for predicting overall survival and Cancer-Specific survival in nonmetastatic inflammatory breast cancer patients receiving Tri-Modality therapy: a Population-Based study. Med Sci Monit. 2019;25:9167–9178.

[26] Kudo SE, Ichimasu K, Villard B, et al. Artificial intelligence system to determine risk of T1 colorectal cancer metastasis to lymph node. Gastroenterology. 2021;160(4):1075–1084.e2.

[27] Xu YW, Chen H, Guo HP, et al. Combined detection of serum autoantibodies as diagnostic biomarkers in esophageogastric junction adenocarcinoma. Gastric Cancer. 2019;22(3):546–557.

[28] Camp RL, Dolled-Filhart M, Rimm DL. X-Tile. Clin Cancer Res. 2004;10(21):7252–7259.

[29] Crosby D, Bhatia S, Brindle KM, et al. Early detection of cancer. Science. 2022;375(6586):eaa99040.

[30] Zhang J, Zhu Z, Liu Y, et al. Diagnostic value of multiple tumor markers for patients with esophageal carcinoma. PLoS One. 2015;10(2):e0116951.

[31] Mroczko B, Kozlowski M, Groblewska M, et al. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta. 2008;389(1-2):61–66.

[32] Rice TW, Gress DM, Patil DT, et al. Cancer of the esophagus and esophageogastric junction-Major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):304–317. Jul 8

[33] Hao JJ, Lin DC, Dinh HQ, et al. Spatial intratumoral heterogeneity and temporal clonal evolution in
esophageal squamous cell carcinoma. Nat Genet. 2016;48(12):1500–1507.

[34] Wen J, Wang G, Xie X, et al. Prognostic value of a four-miRNA signature in patients with lymph node positive locoregional esophageal squamous cell carcinoma undergoing complete surgical resection. Ann Surg. 2021;273(3):523–531.

[35] Luo LL, Zhao L, Xi M, et al. Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma. Chin J Cancer. 2015;34(3):514–521.

[36] Chang YS, Kong G, Sun S, et al. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res. 2002;8(12):3796–3802.

[37] Standal T, Borset M, Lenhoff S, et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood. 2002;100(12):3925–3929.

[38] Rocha RL, Hilsenbeck SG, Jackson JG, et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997;3(1):103–109.

[39] Adachi Y, Nojima M, Mori M, et al. Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study. World J Gastroenterol. 2017;23(19):3488–3495.

[40] Song G, Liu K, Zhu X, et al. The low IGFBP-3 level is associated with esophageal cancer patients: a Meta-analysis. World J Surg Oncol. 2016;14(1):307.

[41] Yilmaz O, Eroglu A, Dag E, et al. Serum levels of IGF-I and IGFBP-III and their relation with carcinoembryonic antigen and carbohydrate antigen 19:9 in cases of esophageal cancer. Inter J Clin Pract. 2006;60(12):1604–1608. Dec

[42] Ye P, Qu CF, Hu XL. Impact of IGF-1, IGF-1R, and IGFBP-3 promoter methylation on the risk and prognosis of esophageal carcinoma. Tumour Biol. 2016;37(5):6893–6904.

[43] Tomii K, Tsukuda K, Toyooka S, et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer. 2007;120(3):566–573.

[44] Miyamoto S, Yano K, Sugimoto S, et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 2004;64(2):665–671.

[45] Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. The Lancet Oncology. 2012;13(8):817–826.

[46] Lin XJ, Chong Y, Guo ZW, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015;16(7):804–815.

[47] Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol. 1996;28(6):619–637.

[48] Murphy N, Carreras-Torres R, Song M, et al. Circulating levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 associate with risk of colorectal cancer based on serologic and mendelian randomization analyses. Gastroenterology. 2020;158(5):1300–1312.e20.

[49] Nakayama A, Aoki S, Uchihashi K, et al. Interaction between esophageal squamous cell carcinoma and adipose tissue in vitro. Am J Pathol. 2016;186(5):1180–1194.